Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...

As Alnylam Pharmaceuticals approaches its highly anticipated March 23 FDA decision date for a potential expansion of Amvuttra ...

While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...

Royalty Pharma's Q4 results show portfolio receipts of $742 million and operating cash flow of $678 million. Read why RPRX ...

The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the ...

Vertex Pharmaceuticals continues to leverage its strong cystic fibrosis franchise while advancing a promising pipeline of therapies for other serious diseases. While challenges remain, including ...

Royalty Pharma Plc engages in the provision of drug ... Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta ...

The headline numbers for Royalty Pharma (RPRX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall ...

RBC Capital raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $407 from $402 and keeps a Sector Perform rating on the shares.